IceCure Medical's prelim 2025 revenue misses expectations

Icecure Medical

12/01/2026 13:41

Overview

Israel cryoablation firm's preliminary 2025 revenue missed analyst expectations

Company experienced strong U.S. demand following FDA authorization for ProSense

Record European sales driven by U.S. clearance and growing ProSense adoption

Outlook

IceCure expects higher ProSense® sales in 2026 due to U.S. and European demand

Company anticipates more reimbursement coverage for ProSense® procedures in 2026

Terumo to submit breast cancer clearance request in Japan in first half of 2026

Result Drivers

FDA AUTHORIZATION - U.S. FDA marketing authorization for ProSense® drove strong demand in North America, particularly for low-risk breast cancer treatment in women aged 70 and above

EUROPEAN SALES - Record European sales driven by U.S. clearance and growing adoption of ProSense® cryoablation for breast cancer

CLINICAL EVIDENCE - Record number of peer-reviewed publications and presentations demonstrate growing clinical evidence for ProSense® across various cancer types

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Miss
$3.40 mln
$3.67 mln (2 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Icecure Medical Ltd is $3.13, about 340% above its January 9 closing price of $0.71

Press Release: ID:nPn5QLbNwa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)